nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ORM1—Vismodegib—skin cancer	0.0861	0.135	CbGbCtD
Imatinib—ORM1—Vemurafenib—skin cancer	0.0681	0.107	CbGbCtD
Imatinib—ABCG2—Vismodegib—skin cancer	0.0526	0.0823	CbGbCtD
Imatinib—ABCG2—Vemurafenib—skin cancer	0.0415	0.065	CbGbCtD
Imatinib—ALB—Vismodegib—skin cancer	0.0362	0.0567	CbGbCtD
Imatinib—CYP1A2—Imiquimod—skin cancer	0.0313	0.0489	CbGbCtD
Imatinib—ALB—Vemurafenib—skin cancer	0.0286	0.0448	CbGbCtD
Imatinib—ABCG2—Dactinomycin—skin cancer	0.0276	0.0432	CbGbCtD
Imatinib—CYP2C19—Vismodegib—skin cancer	0.0235	0.0368	CbGbCtD
Imatinib—CYP2C9—Vismodegib—skin cancer	0.0195	0.0306	CbGbCtD
Imatinib—ABCB1—Vismodegib—skin cancer	0.0189	0.0297	CbGbCtD
Imatinib—ABCG2—Fluorouracil—skin cancer	0.0187	0.0292	CbGbCtD
Imatinib—CYP1A2—Vemurafenib—skin cancer	0.0171	0.0268	CbGbCtD
Imatinib—CYP3A4—Temozolomide—skin cancer	0.0164	0.0256	CbGbCtD
Imatinib—CYP3A4—Imiquimod—skin cancer	0.0164	0.0256	CbGbCtD
Imatinib—ABCG2—Docetaxel—skin cancer	0.0143	0.0223	CbGbCtD
Imatinib—CYP2D6—Vemurafenib—skin cancer	0.0141	0.0221	CbGbCtD
Imatinib—CYP1A2—Dacarbazine—skin cancer	0.0131	0.0206	CbGbCtD
Imatinib—ALB—Fluorouracil—skin cancer	0.0129	0.0201	CbGbCtD
Imatinib—CYP3A4—Vismodegib—skin cancer	0.0114	0.0178	CbGbCtD
Imatinib—CYP3A7—Docetaxel—skin cancer	0.0105	0.0165	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0105	0.0165	CbGbCtD
Imatinib—ABCB1—Dactinomycin—skin cancer	0.00995	0.0156	CbGbCtD
Imatinib—CYP3A4—Vemurafenib—skin cancer	0.00897	0.014	CbGbCtD
Imatinib—CYP3A5—Docetaxel—skin cancer	0.0079	0.0124	CbGbCtD
Imatinib—CYP1A2—Fluorouracil—skin cancer	0.0077	0.012	CbGbCtD
Imatinib—CYP2C9—Fluorouracil—skin cancer	0.00693	0.0109	CbGbCtD
Imatinib—ABCB1—Docetaxel—skin cancer	0.00514	0.00805	CbGbCtD
Imatinib—CA6—ear—skin cancer	0.00408	0.049	CbGeAlD
Imatinib—PDGFRA—penis—skin cancer	0.00407	0.0489	CbGeAlD
Imatinib—CA3—ear—skin cancer	0.00386	0.0464	CbGeAlD
Imatinib—DDR1—hair follicle—skin cancer	0.00346	0.0415	CbGeAlD
Imatinib—CYP3A4—Docetaxel—skin cancer	0.00308	0.00482	CbGbCtD
Imatinib—Nilotinib—BRAF—skin cancer	0.00274	1	CrCbGaD
Imatinib—DDR1—nipple—skin cancer	0.00234	0.0282	CbGeAlD
Imatinib—CA6—hair follicle—skin cancer	0.00215	0.0259	CbGeAlD
Imatinib—KIT—skin epidermis—skin cancer	0.00175	0.021	CbGeAlD
Imatinib—ABCA3—mammalian vulva—skin cancer	0.00148	0.0178	CbGeAlD
Imatinib—PIP4K2C—nipple—skin cancer	0.00145	0.0174	CbGeAlD
Imatinib—DDR1—mammalian vulva—skin cancer	0.00137	0.0164	CbGeAlD
Imatinib—CA1—nerve—skin cancer	0.00136	0.0164	CbGeAlD
Imatinib—HIPK4—female reproductive system—skin cancer	0.00128	0.0154	CbGeAlD
Imatinib—LCK—nipple—skin cancer	0.00128	0.0154	CbGeAlD
Imatinib—KIT—endothelium—skin cancer	0.00127	0.0153	CbGeAlD
Imatinib—KIT—blood vessel—skin cancer	0.00117	0.0141	CbGeAlD
Imatinib—PDGFRB—blood vessel—skin cancer	0.00114	0.0138	CbGeAlD
Imatinib—NQO2—nipple—skin cancer	0.00106	0.0128	CbGeAlD
Imatinib—ABCA3—head—skin cancer	0.00106	0.0128	CbGeAlD
Imatinib—CA3—connective tissue—skin cancer	0.00098	0.0118	CbGeAlD
Imatinib—CSF1R—nipple—skin cancer	0.000933	0.0112	CbGeAlD
Imatinib—SLC47A1—nipple—skin cancer	0.000852	0.0102	CbGeAlD
Imatinib—KIT—nipple—skin cancer	0.000847	0.0102	CbGeAlD
Imatinib—PIP4K2C—mammalian vulva—skin cancer	0.000845	0.0102	CbGeAlD
Imatinib—KIT—neck—skin cancer	0.000838	0.0101	CbGeAlD
Imatinib—PDGFRB—nipple—skin cancer	0.000827	0.00994	CbGeAlD
Imatinib—PDGFRB—neck—skin cancer	0.000819	0.00984	CbGeAlD
Imatinib—PDGFRA—connective tissue—skin cancer	0.000752	0.00903	CbGeAlD
Imatinib—LCK—mammalian vulva—skin cancer	0.00075	0.00901	CbGeAlD
Imatinib—ABCA3—lymph node—skin cancer	0.000743	0.00893	CbGeAlD
Imatinib—CA2—hair follicle—skin cancer	0.000741	0.0089	CbGeAlD
Imatinib—ABL1—nipple—skin cancer	0.000737	0.00886	CbGeAlD
Imatinib—PIP4K2C—female reproductive system—skin cancer	0.000723	0.0087	CbGeAlD
Imatinib—CA12—connective tissue—skin cancer	0.000694	0.00834	CbGeAlD
Imatinib—DDR1—lymph node—skin cancer	0.000686	0.00824	CbGeAlD
Imatinib—CSF1R—connective tissue—skin cancer	0.000662	0.00795	CbGeAlD
Imatinib—CA9—female reproductive system—skin cancer	0.000661	0.00795	CbGeAlD
Imatinib—NQO2—mammalian vulva—skin cancer	0.00062	0.00746	CbGeAlD
Imatinib—CA6—head—skin cancer	0.000609	0.00732	CbGeAlD
Imatinib—PIP4K2C—head—skin cancer	0.000604	0.00726	CbGeAlD
Imatinib—KIT—connective tissue—skin cancer	0.000601	0.00722	CbGeAlD
Imatinib—CSF1R—skin of body—skin cancer	0.000597	0.00718	CbGeAlD
Imatinib—PDGFRB—connective tissue—skin cancer	0.000587	0.00705	CbGeAlD
Imatinib—PTGS1—endothelium—skin cancer	0.000582	0.00699	CbGeAlD
Imatinib—CA3—head—skin cancer	0.000577	0.00694	CbGeAlD
Imatinib—KIT—epithelium—skin cancer	0.00057	0.00686	CbGeAlD
Imatinib—PDGFRB—epithelium—skin cancer	0.000557	0.0067	CbGeAlD
Imatinib—PDGFRA—lymphoid tissue—skin cancer	0.00055	0.0066	CbGeAlD
Imatinib—CSF1R—mammalian vulva—skin cancer	0.000545	0.00655	CbGeAlD
Imatinib—KIT—skin of body—skin cancer	0.000543	0.00652	CbGeAlD
Imatinib—PTGS1—blood vessel—skin cancer	0.000536	0.00645	CbGeAlD
Imatinib—NQO2—female reproductive system—skin cancer	0.000531	0.00639	CbGeAlD
Imatinib—PDGFRA—female reproductive system—skin cancer	0.00053	0.00637	CbGeAlD
Imatinib—PDGFRB—skin of body—skin cancer	0.00053	0.00637	CbGeAlD
Imatinib—ABL1—connective tissue—skin cancer	0.000523	0.00629	CbGeAlD
Imatinib—CA2—nipple—skin cancer	0.000502	0.00604	CbGeAlD
Imatinib—SLC47A1—mammalian vulva—skin cancer	0.000498	0.00598	CbGeAlD
Imatinib—CA2—neck—skin cancer	0.000497	0.00597	CbGeAlD
Imatinib—KIT—mammalian vulva—skin cancer	0.000495	0.00595	CbGeAlD
Imatinib—CA12—female reproductive system—skin cancer	0.000489	0.00588	CbGeAlD
Imatinib—CSF1R—lymphoid tissue—skin cancer	0.000484	0.00581	CbGeAlD
Imatinib—PDGFRB—mammalian vulva—skin cancer	0.000483	0.00581	CbGeAlD
Imatinib—ABL1—skin of body—skin cancer	0.000472	0.00568	CbGeAlD
Imatinib—CSF1R—female reproductive system—skin cancer	0.000467	0.00561	CbGeAlD
Imatinib—CYP1A2—nipple—skin cancer	0.000448	0.00538	CbGeAlD
Imatinib—ABL2—lymph node—skin cancer	0.000447	0.00538	CbGeAlD
Imatinib—NQO2—head—skin cancer	0.000444	0.00534	CbGeAlD
Imatinib—PDGFRA—head—skin cancer	0.000443	0.00532	CbGeAlD
Imatinib—KIT—lymphoid tissue—skin cancer	0.000439	0.00528	CbGeAlD
Imatinib—ABL1—mammalian vulva—skin cancer	0.000431	0.00518	CbGeAlD
Imatinib—PDGFRB—lymphoid tissue—skin cancer	0.000429	0.00516	CbGeAlD
Imatinib—SLC47A1—female reproductive system—skin cancer	0.000426	0.00512	CbGeAlD
Imatinib—KIT—female reproductive system—skin cancer	0.000424	0.00509	CbGeAlD
Imatinib—PIP4K2C—lymph node—skin cancer	0.000423	0.00509	CbGeAlD
Imatinib—PDGFRB—female reproductive system—skin cancer	0.000414	0.00497	CbGeAlD
Imatinib—CA12—head—skin cancer	0.000409	0.00491	CbGeAlD
Imatinib—CA3—lymph node—skin cancer	0.000404	0.00486	CbGeAlD
Imatinib—CA1—lymphoid tissue—skin cancer	0.000402	0.00483	CbGeAlD
Imatinib—CSF1R—head—skin cancer	0.00039	0.00469	CbGeAlD
Imatinib—ORM1—female reproductive system—skin cancer	0.000388	0.00467	CbGeAlD
Imatinib—PTGS1—nipple—skin cancer	0.000388	0.00466	CbGeAlD
Imatinib—CA1—female reproductive system—skin cancer	0.000388	0.00466	CbGeAlD
Imatinib—ABL1—lymphoid tissue—skin cancer	0.000382	0.0046	CbGeAlD
Imatinib—LCK—lymph node—skin cancer	0.000376	0.00452	CbGeAlD
Imatinib—ABL1—female reproductive system—skin cancer	0.000369	0.00443	CbGeAlD
Imatinib—CA2—connective tissue—skin cancer	0.000356	0.00428	CbGeAlD
Imatinib—SLC47A1—head—skin cancer	0.000356	0.00428	CbGeAlD
Imatinib—KIT—head—skin cancer	0.000354	0.00425	CbGeAlD
Imatinib—PDGFRB—head—skin cancer	0.000346	0.00416	CbGeAlD
Imatinib—CA2—epithelium—skin cancer	0.000338	0.00406	CbGeAlD
Imatinib—CA1—head—skin cancer	0.000324	0.00389	CbGeAlD
Imatinib—CA2—skin of body—skin cancer	0.000322	0.00387	CbGeAlD
Imatinib—ABCB1—blood vessel—skin cancer	0.000317	0.00381	CbGeAlD
Imatinib—NQO2—lymph node—skin cancer	0.000311	0.00374	CbGeAlD
Imatinib—PDGFRA—lymph node—skin cancer	0.00031	0.00373	CbGeAlD
Imatinib—ABL1—head—skin cancer	0.000308	0.0037	CbGeAlD
Imatinib—SLC22A1—head—skin cancer	0.000297	0.00357	CbGeAlD
Imatinib—CA2—mammalian vulva—skin cancer	0.000293	0.00352	CbGeAlD
Imatinib—PTGS1—connective tissue—skin cancer	0.000275	0.00331	CbGeAlD
Imatinib—CSF1R—lymph node—skin cancer	0.000273	0.00328	CbGeAlD
Imatinib—ABCG2—mammalian vulva—skin cancer	0.000272	0.00326	CbGeAlD
Imatinib—PTGS1—epithelium—skin cancer	0.000261	0.00314	CbGeAlD
Imatinib—CA2—lymphoid tissue—skin cancer	0.00026	0.00313	CbGeAlD
Imatinib—CA2—female reproductive system—skin cancer	0.000251	0.00302	CbGeAlD
Imatinib—SLC47A1—lymph node—skin cancer	0.000249	0.003	CbGeAlD
Imatinib—PTGS1—skin of body—skin cancer	0.000248	0.00299	CbGeAlD
Imatinib—KIT—lymph node—skin cancer	0.000248	0.00298	CbGeAlD
Imatinib—PDGFRB—lymph node—skin cancer	0.000242	0.00291	CbGeAlD
Imatinib—ORM1—lymph node—skin cancer	0.000227	0.00273	CbGeAlD
Imatinib—CA1—lymph node—skin cancer	0.000227	0.00272	CbGeAlD
Imatinib—PTGS1—mammalian vulva—skin cancer	0.000227	0.00272	CbGeAlD
Imatinib—ABL1—lymph node—skin cancer	0.000216	0.00259	CbGeAlD
Imatinib—CYP2C9—female reproductive system—skin cancer	0.000212	0.00255	CbGeAlD
Imatinib—CA2—head—skin cancer	0.00021	0.00252	CbGeAlD
Imatinib—ALB—lymph node—skin cancer	0.000199	0.00239	CbGeAlD
Imatinib—PTGS1—female reproductive system—skin cancer	0.000194	0.00233	CbGeAlD
Imatinib—PTGS1—head—skin cancer	0.000162	0.00195	CbGeAlD
Imatinib—CYP3A4—female reproductive system—skin cancer	0.000162	0.00195	CbGeAlD
Imatinib—CYP2D6—female reproductive system—skin cancer	0.000159	0.00192	CbGeAlD
Imatinib—ABCB1—epithelium—skin cancer	0.000154	0.00186	CbGeAlD
Imatinib—CA2—lymph node—skin cancer	0.000147	0.00177	CbGeAlD
Imatinib—Discomfort—Bleomycin—skin cancer	0.000145	0.000688	CcSEcCtD
Imatinib—Malaise—Dactinomycin—skin cancer	0.000145	0.000688	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000144	0.000686	CcSEcCtD
Imatinib—Cramp muscle—Docetaxel—skin cancer	0.000144	0.000686	CcSEcCtD
Imatinib—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000144	0.000686	CcSEcCtD
Imatinib—Leukopenia—Dactinomycin—skin cancer	0.000144	0.000683	CcSEcCtD
Imatinib—Nasopharyngitis—Docetaxel—skin cancer	0.000143	0.000681	CcSEcCtD
Imatinib—Dysgeusia—Temozolomide—skin cancer	0.000142	0.000675	CcSEcCtD
Imatinib—Asthenia—Imiquimod—skin cancer	0.000142	0.000674	CcSEcCtD
Imatinib—Confusional state—Bleomycin—skin cancer	0.000142	0.000673	CcSEcCtD
Imatinib—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000141	0.000672	CcSEcCtD
Imatinib—Oedema—Bleomycin—skin cancer	0.000141	0.000667	CcSEcCtD
Imatinib—Anaphylactic shock—Bleomycin—skin cancer	0.000141	0.000667	CcSEcCtD
Imatinib—Back pain—Temozolomide—skin cancer	0.000141	0.000667	CcSEcCtD
Imatinib—Pruritus—Imiquimod—skin cancer	0.00014	0.000665	CcSEcCtD
Imatinib—Infection—Bleomycin—skin cancer	0.00014	0.000663	CcSEcCtD
Imatinib—Dysphagia—Docetaxel—skin cancer	0.000139	0.000658	CcSEcCtD
Imatinib—Nausea—Vemurafenib—skin cancer	0.000138	0.000654	CcSEcCtD
Imatinib—Thrombocytopenia—Bleomycin—skin cancer	0.000138	0.000653	CcSEcCtD
Imatinib—Arrhythmia—Fluorouracil—skin cancer	0.000137	0.000652	CcSEcCtD
Imatinib—Vision blurred—Temozolomide—skin cancer	0.000137	0.00065	CcSEcCtD
Imatinib—Myalgia—Dactinomycin—skin cancer	0.000137	0.000649	CcSEcCtD
Imatinib—Tremor—Temozolomide—skin cancer	0.000136	0.000646	CcSEcCtD
Imatinib—ABCG2—lymph node—skin cancer	0.000136	0.00164	CbGeAlD
Imatinib—Alopecia—Fluorouracil—skin cancer	0.000136	0.000645	CcSEcCtD
Imatinib—Diarrhoea—Imiquimod—skin cancer	0.000135	0.000643	CcSEcCtD
Imatinib—Discomfort—Dactinomycin—skin cancer	0.000135	0.000641	CcSEcCtD
Imatinib—Angina pectoris—Docetaxel—skin cancer	0.000135	0.000641	CcSEcCtD
Imatinib—Ill-defined disorder—Temozolomide—skin cancer	0.000135	0.00064	CcSEcCtD
Imatinib—Anaemia—Temozolomide—skin cancer	0.000134	0.000638	CcSEcCtD
Imatinib—Anorexia—Bleomycin—skin cancer	0.000134	0.000636	CcSEcCtD
Imatinib—ABCB1—mammalian vulva—skin cancer	0.000134	0.00161	CbGeAlD
Imatinib—Erythema—Fluorouracil—skin cancer	0.000134	0.000636	CcSEcCtD
Imatinib—CYP2D6—head—skin cancer	0.000133	0.0016	CbGeAlD
Imatinib—Angioedema—Temozolomide—skin cancer	0.000133	0.00063	CcSEcCtD
Imatinib—Pancytopenia—Docetaxel—skin cancer	0.000132	0.000625	CcSEcCtD
Imatinib—Hypotension—Bleomycin—skin cancer	0.000131	0.000624	CcSEcCtD
Imatinib—Oedema—Dactinomycin—skin cancer	0.000131	0.000622	CcSEcCtD
Imatinib—Malaise—Temozolomide—skin cancer	0.000131	0.000622	CcSEcCtD
Imatinib—Dizziness—Imiquimod—skin cancer	0.000131	0.000621	CcSEcCtD
Imatinib—Vertigo—Temozolomide—skin cancer	0.000131	0.00062	CcSEcCtD
Imatinib—Infection—Dactinomycin—skin cancer	0.00013	0.000618	CcSEcCtD
Imatinib—Leukopenia—Temozolomide—skin cancer	0.00013	0.000617	CcSEcCtD
Imatinib—Neutropenia—Docetaxel—skin cancer	0.00013	0.000616	CcSEcCtD
Imatinib—Palpitations—Temozolomide—skin cancer	0.000128	0.00061	CcSEcCtD
Imatinib—Thrombocytopenia—Dactinomycin—skin cancer	0.000128	0.000609	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000128	0.000608	CcSEcCtD
Imatinib—Cough—Temozolomide—skin cancer	0.000127	0.000602	CcSEcCtD
Imatinib—Paraesthesia—Bleomycin—skin cancer	0.000126	0.000599	CcSEcCtD
Imatinib—Weight increased—Docetaxel—skin cancer	0.000126	0.000599	CcSEcCtD
Imatinib—Vision blurred—Fluorouracil—skin cancer	0.000126	0.000599	CcSEcCtD
Imatinib—Convulsion—Temozolomide—skin cancer	0.000126	0.000598	CcSEcCtD
Imatinib—Vomiting—Imiquimod—skin cancer	0.000126	0.000597	CcSEcCtD
Imatinib—Weight decreased—Docetaxel—skin cancer	0.000125	0.000596	CcSEcCtD
Imatinib—Hypertension—Temozolomide—skin cancer	0.000125	0.000595	CcSEcCtD
Imatinib—Dyspnoea—Bleomycin—skin cancer	0.000125	0.000595	CcSEcCtD
Imatinib—Anorexia—Dactinomycin—skin cancer	0.000125	0.000593	CcSEcCtD
Imatinib—Rash—Imiquimod—skin cancer	0.000125	0.000592	CcSEcCtD
Imatinib—Dermatitis—Imiquimod—skin cancer	0.000125	0.000592	CcSEcCtD
Imatinib—Pneumonia—Docetaxel—skin cancer	0.000124	0.00059	CcSEcCtD
Imatinib—Headache—Imiquimod—skin cancer	0.000124	0.000588	CcSEcCtD
Imatinib—Anaemia—Fluorouracil—skin cancer	0.000124	0.000587	CcSEcCtD
Imatinib—Myalgia—Temozolomide—skin cancer	0.000124	0.000587	CcSEcCtD
Imatinib—Arthralgia—Temozolomide—skin cancer	0.000124	0.000587	CcSEcCtD
Imatinib—Infestation NOS—Docetaxel—skin cancer	0.000124	0.000587	CcSEcCtD
Imatinib—Infestation—Docetaxel—skin cancer	0.000124	0.000587	CcSEcCtD
Imatinib—Anxiety—Temozolomide—skin cancer	0.000123	0.000585	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000123	0.000583	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000123	0.000582	CcSEcCtD
Imatinib—Discomfort—Temozolomide—skin cancer	0.000122	0.00058	CcSEcCtD
Imatinib—Decreased appetite—Bleomycin—skin cancer	0.000122	0.00058	CcSEcCtD
Imatinib—Acute coronary syndrome—Docetaxel—skin cancer	0.000122	0.000579	CcSEcCtD
Imatinib—Renal failure—Docetaxel—skin cancer	0.000122	0.000577	CcSEcCtD
Imatinib—Neuropathy peripheral—Docetaxel—skin cancer	0.000121	0.000575	CcSEcCtD
Imatinib—Myocardial infarction—Docetaxel—skin cancer	0.000121	0.000575	CcSEcCtD
Imatinib—Dry mouth—Temozolomide—skin cancer	0.000121	0.000574	CcSEcCtD
Imatinib—Stomatitis—Docetaxel—skin cancer	0.000121	0.000572	CcSEcCtD
Imatinib—Jaundice—Docetaxel—skin cancer	0.000121	0.000572	CcSEcCtD
Imatinib—Pain—Bleomycin—skin cancer	0.00012	0.000571	CcSEcCtD
Imatinib—Conjunctivitis—Docetaxel—skin cancer	0.00012	0.000571	CcSEcCtD
Imatinib—Leukopenia—Fluorouracil—skin cancer	0.00012	0.000569	CcSEcCtD
Imatinib—Confusional state—Temozolomide—skin cancer	0.00012	0.000568	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000119	0.000567	CcSEcCtD
Imatinib—ABCB1—lymphoid tissue—skin cancer	0.000119	0.00143	CbGeAlD
Imatinib—Oedema—Temozolomide—skin cancer	0.000119	0.000563	CcSEcCtD
Imatinib—Anaphylactic shock—Temozolomide—skin cancer	0.000119	0.000563	CcSEcCtD
Imatinib—Infection—Temozolomide—skin cancer	0.000118	0.000559	CcSEcCtD
Imatinib—Nausea—Imiquimod—skin cancer	0.000118	0.000558	CcSEcCtD
Imatinib—Hepatobiliary disease—Docetaxel—skin cancer	0.000117	0.000555	CcSEcCtD
Imatinib—Epistaxis—Docetaxel—skin cancer	0.000117	0.000554	CcSEcCtD
Imatinib—Nervous system disorder—Temozolomide—skin cancer	0.000116	0.000552	CcSEcCtD
Imatinib—Thrombocytopenia—Temozolomide—skin cancer	0.000116	0.000551	CcSEcCtD
Imatinib—Convulsion—Fluorouracil—skin cancer	0.000116	0.000551	CcSEcCtD
Imatinib—Feeling abnormal—Bleomycin—skin cancer	0.000116	0.00055	CcSEcCtD
Imatinib—Agranulocytosis—Docetaxel—skin cancer	0.000115	0.000548	CcSEcCtD
Imatinib—Skin disorder—Temozolomide—skin cancer	0.000115	0.000547	CcSEcCtD
Imatinib—ABCB1—female reproductive system—skin cancer	0.000115	0.00138	CbGeAlD
Imatinib—Hyperhidrosis—Temozolomide—skin cancer	0.000115	0.000544	CcSEcCtD
Imatinib—Chest pain—Fluorouracil—skin cancer	0.000114	0.000541	CcSEcCtD
Imatinib—Myalgia—Fluorouracil—skin cancer	0.000114	0.000541	CcSEcCtD
Imatinib—Decreased appetite—Dactinomycin—skin cancer	0.000114	0.000541	CcSEcCtD
Imatinib—PTGS1—lymph node—skin cancer	0.000113	0.00136	CbGeAlD
Imatinib—Fatigue—Dactinomycin—skin cancer	0.000113	0.000537	CcSEcCtD
Imatinib—Anorexia—Temozolomide—skin cancer	0.000113	0.000537	CcSEcCtD
Imatinib—Discomfort—Fluorouracil—skin cancer	0.000113	0.000535	CcSEcCtD
Imatinib—Pain—Dactinomycin—skin cancer	0.000112	0.000532	CcSEcCtD
Imatinib—Urticaria—Bleomycin—skin cancer	0.000112	0.00053	CcSEcCtD
Imatinib—Haemoglobin—Docetaxel—skin cancer	0.000112	0.00053	CcSEcCtD
Imatinib—Rhinitis—Docetaxel—skin cancer	0.000111	0.000528	CcSEcCtD
Imatinib—Body temperature increased—Bleomycin—skin cancer	0.000111	0.000528	CcSEcCtD
Imatinib—Haemorrhage—Docetaxel—skin cancer	0.000111	0.000527	CcSEcCtD
Imatinib—Hepatitis—Docetaxel—skin cancer	0.000111	0.000527	CcSEcCtD
Imatinib—Hypoaesthesia—Docetaxel—skin cancer	0.00011	0.000524	CcSEcCtD
Imatinib—Confusional state—Fluorouracil—skin cancer	0.00011	0.000523	CcSEcCtD
Imatinib—Pharyngitis—Docetaxel—skin cancer	0.00011	0.000523	CcSEcCtD
Imatinib—Urinary tract disorder—Docetaxel—skin cancer	0.00011	0.00052	CcSEcCtD
Imatinib—Oedema peripheral—Docetaxel—skin cancer	0.000109	0.000519	CcSEcCtD
Imatinib—Anaphylactic shock—Fluorouracil—skin cancer	0.000109	0.000519	CcSEcCtD
Imatinib—Oedema—Fluorouracil—skin cancer	0.000109	0.000519	CcSEcCtD
Imatinib—Connective tissue disorder—Docetaxel—skin cancer	0.000109	0.000518	CcSEcCtD
Imatinib—Urethral disorder—Docetaxel—skin cancer	0.000109	0.000517	CcSEcCtD
Imatinib—Infection—Fluorouracil—skin cancer	0.000109	0.000515	CcSEcCtD
Imatinib—Feeling abnormal—Dactinomycin—skin cancer	0.000108	0.000513	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000108	0.000513	CcSEcCtD
Imatinib—Insomnia—Temozolomide—skin cancer	0.000107	0.000509	CcSEcCtD
Imatinib—Gastrointestinal pain—Dactinomycin—skin cancer	0.000107	0.000509	CcSEcCtD
Imatinib—Nervous system disorder—Fluorouracil—skin cancer	0.000107	0.000509	CcSEcCtD
Imatinib—Thrombocytopenia—Fluorouracil—skin cancer	0.000107	0.000508	CcSEcCtD
Imatinib—Tachycardia—Fluorouracil—skin cancer	0.000107	0.000506	CcSEcCtD
Imatinib—Paraesthesia—Temozolomide—skin cancer	0.000106	0.000505	CcSEcCtD
Imatinib—Dyspnoea—Temozolomide—skin cancer	0.000106	0.000502	CcSEcCtD
Imatinib—Somnolence—Temozolomide—skin cancer	0.000105	0.0005	CcSEcCtD
Imatinib—Erythema multiforme—Docetaxel—skin cancer	0.000105	0.000498	CcSEcCtD
Imatinib—Dyspepsia—Temozolomide—skin cancer	0.000104	0.000496	CcSEcCtD
Imatinib—Anorexia—Fluorouracil—skin cancer	0.000104	0.000494	CcSEcCtD
Imatinib—Eye disorder—Docetaxel—skin cancer	0.000104	0.000492	CcSEcCtD
Imatinib—Abdominal pain—Dactinomycin—skin cancer	0.000104	0.000492	CcSEcCtD
Imatinib—Body temperature increased—Dactinomycin—skin cancer	0.000104	0.000492	CcSEcCtD
Imatinib—Hypersensitivity—Bleomycin—skin cancer	0.000104	0.000492	CcSEcCtD
Imatinib—Decreased appetite—Temozolomide—skin cancer	0.000103	0.000489	CcSEcCtD
Imatinib—Flushing—Docetaxel—skin cancer	0.000103	0.000489	CcSEcCtD
Imatinib—Cardiac disorder—Docetaxel—skin cancer	0.000103	0.000489	CcSEcCtD
Imatinib—Gastrointestinal disorder—Temozolomide—skin cancer	0.000102	0.000486	CcSEcCtD
Imatinib—Fatigue—Temozolomide—skin cancer	0.000102	0.000485	CcSEcCtD
Imatinib—Hypotension—Fluorouracil—skin cancer	0.000102	0.000485	CcSEcCtD
Imatinib—Constipation—Temozolomide—skin cancer	0.000101	0.000481	CcSEcCtD
Imatinib—Pain—Temozolomide—skin cancer	0.000101	0.000481	CcSEcCtD
Imatinib—Asthenia—Bleomycin—skin cancer	0.000101	0.000479	CcSEcCtD
Imatinib—Angiopathy—Docetaxel—skin cancer	0.000101	0.000478	CcSEcCtD
Imatinib—Immune system disorder—Docetaxel—skin cancer	0.0001	0.000476	CcSEcCtD
Imatinib—Mediastinal disorder—Docetaxel—skin cancer	0.0001	0.000475	CcSEcCtD
Imatinib—Chills—Docetaxel—skin cancer	9.96e-05	0.000473	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Fluorouracil—skin cancer	9.95e-05	0.000473	CcSEcCtD
Imatinib—Pruritus—Bleomycin—skin cancer	9.94e-05	0.000472	CcSEcCtD
Imatinib—Arrhythmia—Docetaxel—skin cancer	9.91e-05	0.000471	CcSEcCtD
Imatinib—Insomnia—Fluorouracil—skin cancer	9.88e-05	0.000469	CcSEcCtD
Imatinib—Paraesthesia—Fluorouracil—skin cancer	9.81e-05	0.000466	CcSEcCtD
Imatinib—Alopecia—Docetaxel—skin cancer	9.81e-05	0.000466	CcSEcCtD
Imatinib—Feeling abnormal—Temozolomide—skin cancer	9.77e-05	0.000464	CcSEcCtD
Imatinib—Dyspnoea—Fluorouracil—skin cancer	9.74e-05	0.000462	CcSEcCtD
Imatinib—Mental disorder—Docetaxel—skin cancer	9.72e-05	0.000462	CcSEcCtD
Imatinib—Somnolence—Fluorouracil—skin cancer	9.71e-05	0.000461	CcSEcCtD
Imatinib—Gastrointestinal pain—Temozolomide—skin cancer	9.69e-05	0.00046	CcSEcCtD
Imatinib—Erythema—Docetaxel—skin cancer	9.66e-05	0.000459	CcSEcCtD
Imatinib—Malnutrition—Docetaxel—skin cancer	9.66e-05	0.000459	CcSEcCtD
Imatinib—Hypersensitivity—Dactinomycin—skin cancer	9.66e-05	0.000459	CcSEcCtD
Imatinib—Dyspepsia—Fluorouracil—skin cancer	9.62e-05	0.000457	CcSEcCtD
Imatinib—ABCB1—head—skin cancer	9.58e-05	0.00115	CbGeAlD
Imatinib—Decreased appetite—Fluorouracil—skin cancer	9.5e-05	0.000451	CcSEcCtD
Imatinib—Dysgeusia—Docetaxel—skin cancer	9.46e-05	0.000449	CcSEcCtD
Imatinib—Gastrointestinal disorder—Fluorouracil—skin cancer	9.43e-05	0.000448	CcSEcCtD
Imatinib—Urticaria—Temozolomide—skin cancer	9.42e-05	0.000447	CcSEcCtD
Imatinib—Asthenia—Dactinomycin—skin cancer	9.4e-05	0.000447	CcSEcCtD
Imatinib—Body temperature increased—Temozolomide—skin cancer	9.37e-05	0.000445	CcSEcCtD
Imatinib—Abdominal pain—Temozolomide—skin cancer	9.37e-05	0.000445	CcSEcCtD
Imatinib—Back pain—Docetaxel—skin cancer	9.34e-05	0.000444	CcSEcCtD
Imatinib—Pain—Fluorouracil—skin cancer	9.34e-05	0.000444	CcSEcCtD
Imatinib—Muscle spasms—Docetaxel—skin cancer	9.29e-05	0.000441	CcSEcCtD
Imatinib—Feeling abnormal—Fluorouracil—skin cancer	9e-05	0.000427	CcSEcCtD
Imatinib—Diarrhoea—Dactinomycin—skin cancer	8.97e-05	0.000426	CcSEcCtD
Imatinib—Vomiting—Bleomycin—skin cancer	8.94e-05	0.000424	CcSEcCtD
Imatinib—Anaemia—Docetaxel—skin cancer	8.93e-05	0.000424	CcSEcCtD
Imatinib—Rash—Bleomycin—skin cancer	8.86e-05	0.000421	CcSEcCtD
Imatinib—Dermatitis—Bleomycin—skin cancer	8.85e-05	0.00042	CcSEcCtD
Imatinib—Hypersensitivity—Temozolomide—skin cancer	8.74e-05	0.000415	CcSEcCtD
Imatinib—Urticaria—Fluorouracil—skin cancer	8.68e-05	0.000412	CcSEcCtD
Imatinib—Syncope—Docetaxel—skin cancer	8.66e-05	0.000411	CcSEcCtD
Imatinib—Leukopenia—Docetaxel—skin cancer	8.65e-05	0.000411	CcSEcCtD
Imatinib—Body temperature increased—Fluorouracil—skin cancer	8.64e-05	0.00041	CcSEcCtD
Imatinib—Palpitations—Docetaxel—skin cancer	8.54e-05	0.000405	CcSEcCtD
Imatinib—Asthenia—Temozolomide—skin cancer	8.51e-05	0.000404	CcSEcCtD
Imatinib—Loss of consciousness—Docetaxel—skin cancer	8.49e-05	0.000403	CcSEcCtD
Imatinib—Cough—Docetaxel—skin cancer	8.43e-05	0.0004	CcSEcCtD
Imatinib—Pruritus—Temozolomide—skin cancer	8.39e-05	0.000398	CcSEcCtD
Imatinib—Convulsion—Docetaxel—skin cancer	8.37e-05	0.000397	CcSEcCtD
Imatinib—Nausea—Bleomycin—skin cancer	8.35e-05	0.000396	CcSEcCtD
Imatinib—Hypertension—Docetaxel—skin cancer	8.34e-05	0.000396	CcSEcCtD
Imatinib—Vomiting—Dactinomycin—skin cancer	8.33e-05	0.000396	CcSEcCtD
Imatinib—Rash—Dactinomycin—skin cancer	8.27e-05	0.000392	CcSEcCtD
Imatinib—Arthralgia—Docetaxel—skin cancer	8.22e-05	0.000391	CcSEcCtD
Imatinib—Chest pain—Docetaxel—skin cancer	8.22e-05	0.000391	CcSEcCtD
Imatinib—Myalgia—Docetaxel—skin cancer	8.22e-05	0.000391	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	8.17e-05	0.000388	CcSEcCtD
Imatinib—Diarrhoea—Temozolomide—skin cancer	8.11e-05	0.000385	CcSEcCtD
Imatinib—Hypersensitivity—Fluorouracil—skin cancer	8.05e-05	0.000382	CcSEcCtD
Imatinib—Dry mouth—Docetaxel—skin cancer	8.04e-05	0.000382	CcSEcCtD
Imatinib—Confusional state—Docetaxel—skin cancer	7.95e-05	0.000377	CcSEcCtD
Imatinib—Oedema—Docetaxel—skin cancer	7.88e-05	0.000374	CcSEcCtD
Imatinib—Anaphylactic shock—Docetaxel—skin cancer	7.88e-05	0.000374	CcSEcCtD
Imatinib—Dizziness—Temozolomide—skin cancer	7.84e-05	0.000372	CcSEcCtD
Imatinib—Infection—Docetaxel—skin cancer	7.83e-05	0.000372	CcSEcCtD
Imatinib—Nausea—Dactinomycin—skin cancer	7.79e-05	0.00037	CcSEcCtD
Imatinib—Shock—Docetaxel—skin cancer	7.76e-05	0.000368	CcSEcCtD
Imatinib—Nervous system disorder—Docetaxel—skin cancer	7.73e-05	0.000367	CcSEcCtD
Imatinib—Pruritus—Fluorouracil—skin cancer	7.73e-05	0.000367	CcSEcCtD
Imatinib—Thrombocytopenia—Docetaxel—skin cancer	7.72e-05	0.000367	CcSEcCtD
Imatinib—Tachycardia—Docetaxel—skin cancer	7.7e-05	0.000365	CcSEcCtD
Imatinib—Skin disorder—Docetaxel—skin cancer	7.66e-05	0.000364	CcSEcCtD
Imatinib—Vomiting—Temozolomide—skin cancer	7.54e-05	0.000358	CcSEcCtD
Imatinib—Anorexia—Docetaxel—skin cancer	7.52e-05	0.000357	CcSEcCtD
Imatinib—Rash—Temozolomide—skin cancer	7.48e-05	0.000355	CcSEcCtD
Imatinib—Diarrhoea—Fluorouracil—skin cancer	7.47e-05	0.000355	CcSEcCtD
Imatinib—Dermatitis—Temozolomide—skin cancer	7.47e-05	0.000355	CcSEcCtD
Imatinib—Headache—Temozolomide—skin cancer	7.43e-05	0.000353	CcSEcCtD
Imatinib—Hypotension—Docetaxel—skin cancer	7.37e-05	0.00035	CcSEcCtD
Imatinib—Dizziness—Fluorouracil—skin cancer	7.22e-05	0.000343	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Docetaxel—skin cancer	7.18e-05	0.000341	CcSEcCtD
Imatinib—Insomnia—Docetaxel—skin cancer	7.13e-05	0.000339	CcSEcCtD
Imatinib—Paraesthesia—Docetaxel—skin cancer	7.08e-05	0.000336	CcSEcCtD
Imatinib—Nausea—Temozolomide—skin cancer	7.04e-05	0.000334	CcSEcCtD
Imatinib—Dyspnoea—Docetaxel—skin cancer	7.03e-05	0.000334	CcSEcCtD
Imatinib—Somnolence—Docetaxel—skin cancer	7.01e-05	0.000333	CcSEcCtD
Imatinib—Vomiting—Fluorouracil—skin cancer	6.95e-05	0.00033	CcSEcCtD
Imatinib—Dyspepsia—Docetaxel—skin cancer	6.94e-05	0.00033	CcSEcCtD
Imatinib—Rash—Fluorouracil—skin cancer	6.89e-05	0.000327	CcSEcCtD
Imatinib—Dermatitis—Fluorouracil—skin cancer	6.88e-05	0.000327	CcSEcCtD
Imatinib—Decreased appetite—Docetaxel—skin cancer	6.85e-05	0.000325	CcSEcCtD
Imatinib—Headache—Fluorouracil—skin cancer	6.84e-05	0.000325	CcSEcCtD
Imatinib—Gastrointestinal disorder—Docetaxel—skin cancer	6.81e-05	0.000323	CcSEcCtD
Imatinib—Fatigue—Docetaxel—skin cancer	6.8e-05	0.000323	CcSEcCtD
Imatinib—Pain—Docetaxel—skin cancer	6.74e-05	0.00032	CcSEcCtD
Imatinib—Constipation—Docetaxel—skin cancer	6.74e-05	0.00032	CcSEcCtD
Imatinib—ABCB1—lymph node—skin cancer	6.71e-05	0.000806	CbGeAlD
Imatinib—Feeling abnormal—Docetaxel—skin cancer	6.5e-05	0.000308	CcSEcCtD
Imatinib—Nausea—Fluorouracil—skin cancer	6.49e-05	0.000308	CcSEcCtD
Imatinib—Gastrointestinal pain—Docetaxel—skin cancer	6.45e-05	0.000306	CcSEcCtD
Imatinib—Body temperature increased—Docetaxel—skin cancer	6.23e-05	0.000296	CcSEcCtD
Imatinib—Abdominal pain—Docetaxel—skin cancer	6.23e-05	0.000296	CcSEcCtD
Imatinib—Hypersensitivity—Docetaxel—skin cancer	5.81e-05	0.000276	CcSEcCtD
Imatinib—Asthenia—Docetaxel—skin cancer	5.66e-05	0.000269	CcSEcCtD
Imatinib—Pruritus—Docetaxel—skin cancer	5.58e-05	0.000265	CcSEcCtD
Imatinib—Diarrhoea—Docetaxel—skin cancer	5.39e-05	0.000256	CcSEcCtD
Imatinib—Dizziness—Docetaxel—skin cancer	5.21e-05	0.000248	CcSEcCtD
Imatinib—Vomiting—Docetaxel—skin cancer	5.01e-05	0.000238	CcSEcCtD
Imatinib—Rash—Docetaxel—skin cancer	4.97e-05	0.000236	CcSEcCtD
Imatinib—Dermatitis—Docetaxel—skin cancer	4.97e-05	0.000236	CcSEcCtD
Imatinib—Headache—Docetaxel—skin cancer	4.94e-05	0.000235	CcSEcCtD
Imatinib—Nausea—Docetaxel—skin cancer	4.68e-05	0.000222	CcSEcCtD
Imatinib—PDGFRA—Signaling Pathways—PTCH1—skin cancer	1.91e-05	0.000295	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SMO—skin cancer	1.91e-05	0.000295	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SUFU—skin cancer	1.91e-05	0.000295	CbGpPWpGaD
Imatinib—ALB—Metabolism—PLIN2—skin cancer	1.9e-05	0.000293	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR in disease—IL6—skin cancer	1.89e-05	0.000292	CbGpPWpGaD
Imatinib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	1.89e-05	0.000292	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—IL6—skin cancer	1.89e-05	0.000292	CbGpPWpGaD
Imatinib—KIT—Signaling by NGF—IL6—skin cancer	1.88e-05	0.00029	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR—IL6—skin cancer	1.87e-05	0.000289	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—NRAS—skin cancer	1.87e-05	0.000289	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—HRAS—skin cancer	1.86e-05	0.000287	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTGER4—skin cancer	1.86e-05	0.000287	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR in Cancer—IL6—skin cancer	1.85e-05	0.000286	CbGpPWpGaD
Imatinib—LCK—Signaling by PDGF—IL6—skin cancer	1.84e-05	0.000285	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—NRAS—skin cancer	1.83e-05	0.000284	CbGpPWpGaD
Imatinib—LCK—Immune System—FOXO4—skin cancer	1.83e-05	0.000284	CbGpPWpGaD
Imatinib—LCK—B Cell Activation—HRAS—skin cancer	1.82e-05	0.000282	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SHH—skin cancer	1.81e-05	0.00028	CbGpPWpGaD
Imatinib—CA12—Metabolism—PTGS2—skin cancer	1.8e-05	0.000279	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RASA1—skin cancer	1.8e-05	0.000278	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—IL6—skin cancer	1.78e-05	0.000275	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CSPG4—skin cancer	1.78e-05	0.000275	CbGpPWpGaD
Imatinib—KIT—Disease—ERCC2—skin cancer	1.76e-05	0.000273	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	1.75e-05	0.00027	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—KRAS—skin cancer	1.74e-05	0.000268	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—FOXO4—skin cancer	1.73e-05	0.000268	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SMO—skin cancer	1.72e-05	0.000266	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTCH1—skin cancer	1.72e-05	0.000266	CbGpPWpGaD
Imatinib—SLC22A2—Transmission across Chemical Synapses—HRAS—skin cancer	1.71e-05	0.000265	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.71e-05	0.000264	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PLIN2—skin cancer	1.7e-05	0.000263	CbGpPWpGaD
Imatinib—LCK—Disease—FOXO4—skin cancer	1.69e-05	0.000262	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ENO2—skin cancer	1.68e-05	0.000261	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—HRAS—skin cancer	1.67e-05	0.000259	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTGER4—skin cancer	1.67e-05	0.000259	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	1.67e-05	0.000258	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ENO2—skin cancer	1.67e-05	0.000258	CbGpPWpGaD
Imatinib—PDGFRA—Disease—ERCC2—skin cancer	1.67e-05	0.000258	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ENO2—skin cancer	1.67e-05	0.000258	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PLIN2—skin cancer	1.66e-05	0.000257	CbGpPWpGaD
Imatinib—KIT—Disease—TERT—skin cancer	1.65e-05	0.000255	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—FOXO4—skin cancer	1.64e-05	0.000254	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ENO2—skin cancer	1.62e-05	0.00025	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—KRAS—skin cancer	1.61e-05	0.000248	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—IL6—skin cancer	1.6e-05	0.000248	CbGpPWpGaD
Imatinib—SLC22A1—Transmission across Chemical Synapses—HRAS—skin cancer	1.6e-05	0.000247	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—KRAS—skin cancer	1.58e-05	0.000244	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TERT—skin cancer	1.58e-05	0.000244	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PLIN2—skin cancer	1.57e-05	0.000242	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TERT—skin cancer	1.56e-05	0.000242	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ENO2—skin cancer	1.55e-05	0.00024	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PLIN2—skin cancer	1.55e-05	0.00024	CbGpPWpGaD
Imatinib—ALB—Metabolism—CSPG4—skin cancer	1.53e-05	0.000237	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—NRAS—skin cancer	1.53e-05	0.000236	CbGpPWpGaD
Imatinib—PDGFRB—Disease—ERCC2—skin cancer	1.5e-05	0.000232	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—FOXO4—skin cancer	1.48e-05	0.000228	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—HRAS—skin cancer	1.48e-05	0.000228	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—NRAS—skin cancer	1.47e-05	0.000227	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SHH—skin cancer	1.45e-05	0.000225	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—NRAS—skin cancer	1.45e-05	0.000224	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RASA1—skin cancer	1.45e-05	0.000223	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—NRAS—skin cancer	1.44e-05	0.000223	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—IL6—skin cancer	1.41e-05	0.000218	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—NRAS—skin cancer	1.41e-05	0.000218	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TERT—skin cancer	1.41e-05	0.000218	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—NRAS—skin cancer	1.39e-05	0.000215	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SMO—skin cancer	1.38e-05	0.000213	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTCH1—skin cancer	1.38e-05	0.000213	CbGpPWpGaD
Imatinib—CA2—Metabolism—PTGS2—skin cancer	1.38e-05	0.000213	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CSPG4—skin cancer	1.37e-05	0.000212	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HRAS—skin cancer	1.37e-05	0.000211	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—HRAS—skin cancer	1.34e-05	0.000208	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTGER4—skin cancer	1.34e-05	0.000208	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CSPG4—skin cancer	1.34e-05	0.000207	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PLIN2—skin cancer	1.33e-05	0.000205	CbGpPWpGaD
Imatinib—CA1—Metabolism—PTGS2—skin cancer	1.32e-05	0.000204	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—KRAS—skin cancer	1.32e-05	0.000204	CbGpPWpGaD
Imatinib—SLC22A2—Neuronal System—HRAS—skin cancer	1.31e-05	0.000203	CbGpPWpGaD
Imatinib—KIT—Disease—BRAF—skin cancer	1.31e-05	0.000202	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL6—skin cancer	1.31e-05	0.000202	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—NRAS—skin cancer	1.3e-05	0.000202	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—IL6—skin cancer	1.28e-05	0.000199	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—NRAS—skin cancer	1.27e-05	0.000197	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.27e-05	0.000196	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—KRAS—skin cancer	1.26e-05	0.000195	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CSPG4—skin cancer	1.26e-05	0.000195	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—NRAS—skin cancer	1.25e-05	0.000194	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CSPG4—skin cancer	1.25e-05	0.000194	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—BRAF—skin cancer	1.25e-05	0.000193	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—KRAS—skin cancer	1.25e-05	0.000193	CbGpPWpGaD
Imatinib—PDGFRA—Disease—BRAF—skin cancer	1.24e-05	0.000192	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—KRAS—skin cancer	1.24e-05	0.000192	CbGpPWpGaD
Imatinib—SLC22A1—Neuronal System—HRAS—skin cancer	1.22e-05	0.000189	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—KRAS—skin cancer	1.21e-05	0.000188	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ENO2—skin cancer	1.21e-05	0.000187	CbGpPWpGaD
Imatinib—LCK—Disease—ERCC2—skin cancer	1.21e-05	0.000187	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—KRAS—skin cancer	1.2e-05	0.000185	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FOXO4—skin cancer	1.19e-05	0.000183	CbGpPWpGaD
Imatinib—LCK—Hemostasis—NRAS—skin cancer	1.16e-05	0.00018	CbGpPWpGaD
Imatinib—CA9—Metabolism—PTGS2—skin cancer	1.16e-05	0.00018	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TERT—skin cancer	1.16e-05	0.000179	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.14e-05	0.000177	CbGpPWpGaD
Imatinib—LCK—Disease—TERT—skin cancer	1.13e-05	0.000175	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—KRAS—skin cancer	1.12e-05	0.000174	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—HRAS—skin cancer	1.12e-05	0.000173	CbGpPWpGaD
Imatinib—PDGFRB—Disease—BRAF—skin cancer	1.12e-05	0.000173	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TERT—skin cancer	1.1e-05	0.000169	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—KRAS—skin cancer	1.09e-05	0.000169	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—skin cancer	1.08e-05	0.000167	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—KRAS—skin cancer	1.08e-05	0.000167	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HRAS—skin cancer	1.07e-05	0.000166	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—IL6—skin cancer	1.07e-05	0.000166	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CSPG4—skin cancer	1.07e-05	0.000165	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—HRAS—skin cancer	1.06e-05	0.000164	CbGpPWpGaD
Imatinib—KIT—Disease—PTGS2—skin cancer	1.06e-05	0.000163	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—HRAS—skin cancer	1.05e-05	0.000163	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—NRAS—skin cancer	1.05e-05	0.000162	CbGpPWpGaD
Imatinib—ALB—Metabolism—ENO2—skin cancer	1.04e-05	0.000161	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—HRAS—skin cancer	1.03e-05	0.00016	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PLIN2—skin cancer	1.02e-05	0.000158	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HRAS—skin cancer	1.02e-05	0.000157	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.02e-05	0.000157	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—IL6—skin cancer	1.01e-05	0.000157	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—IL6—skin cancer	1.01e-05	0.000156	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—NRAS—skin cancer	1e-05	0.000155	CbGpPWpGaD
Imatinib—LCK—Hemostasis—KRAS—skin cancer	1e-05	0.000155	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PTGS2—skin cancer	1e-05	0.000155	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TERT—skin cancer	9.87e-06	0.000153	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ERCC2—skin cancer	9.79e-06	0.000151	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ERCC2—skin cancer	9.7e-06	0.00015	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ERCC2—skin cancer	9.69e-06	0.00015	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—HRAS—skin cancer	9.54e-06	0.000148	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ERCC2—skin cancer	9.4e-06	0.000145	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ENO2—skin cancer	9.33e-06	0.000144	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—HRAS—skin cancer	9.3e-06	0.000144	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—BRAF—skin cancer	9.16e-06	0.000142	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HRAS—skin cancer	9.16e-06	0.000142	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—IL6—skin cancer	9.13e-06	0.000141	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ENO2—skin cancer	9.11e-06	0.000141	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ERCC2—skin cancer	9.03e-06	0.00014	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PTGS2—skin cancer	9.01e-06	0.000139	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—KRAS—skin cancer	9.01e-06	0.000139	CbGpPWpGaD
Imatinib—LCK—Disease—BRAF—skin cancer	8.95e-06	0.000138	CbGpPWpGaD
Imatinib—KIT—Immune System—NRAS—skin cancer	8.91e-06	0.000138	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—IL6—skin cancer	8.9e-06	0.000138	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—skin cancer	8.89e-06	0.000138	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—BRAF—skin cancer	8.67e-06	0.000134	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—KRAS—skin cancer	8.65e-06	0.000134	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ENO2—skin cancer	8.58e-06	0.000133	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ENO2—skin cancer	8.51e-06	0.000132	CbGpPWpGaD
Imatinib—LCK—Hemostasis—HRAS—skin cancer	8.5e-06	0.000132	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—NRAS—skin cancer	8.43e-06	0.00013	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CSPG4—skin cancer	8.26e-06	0.000128	CbGpPWpGaD
Imatinib—KIT—Disease—NRAS—skin cancer	8.22e-06	0.000127	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.13e-06	0.000126	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TERT—skin cancer	7.92e-06	0.000122	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NRAS—skin cancer	7.86e-06	0.000122	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—BRAF—skin cancer	7.81e-06	0.000121	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NRAS—skin cancer	7.78e-06	0.00012	CbGpPWpGaD
Imatinib—KIT—Immune System—KRAS—skin cancer	7.67e-06	0.000119	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HRAS—skin cancer	7.66e-06	0.000118	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—NRAS—skin cancer	7.6e-06	0.000117	CbGpPWpGaD
Imatinib—ABL1—Immune System—NRAS—skin cancer	7.4e-06	0.000114	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HRAS—skin cancer	7.35e-06	0.000114	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—IL6—skin cancer	7.33e-06	0.000113	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.3e-06	0.000113	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ENO2—skin cancer	7.27e-06	0.000112	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KRAS—skin cancer	7.26e-06	0.000112	CbGpPWpGaD
Imatinib—LCK—Disease—PTGS2—skin cancer	7.23e-06	0.000112	CbGpPWpGaD
Imatinib—KIT—Disease—KRAS—skin cancer	7.08e-06	0.000109	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NRAS—skin cancer	7.01e-06	0.000108	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ERCC2—skin cancer	7.01e-06	0.000108	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NRAS—skin cancer	6.95e-06	0.000107	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—KRAS—skin cancer	6.76e-06	0.000105	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KRAS—skin cancer	6.7e-06	0.000104	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.66e-06	0.000103	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KRAS—skin cancer	6.54e-06	0.000101	CbGpPWpGaD
Imatinib—KIT—Immune System—HRAS—skin cancer	6.52e-06	0.000101	CbGpPWpGaD
Imatinib—ABL1—Immune System—KRAS—skin cancer	6.37e-06	9.85e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—BRAF—skin cancer	6.27e-06	9.7e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—skin cancer	6.24e-06	9.64e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—skin cancer	6.17e-06	9.54e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—NRAS—skin cancer	6.1e-06	9.43e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ERCC2—skin cancer	6.04e-06	9.34e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—skin cancer	6.04e-06	9.33e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—skin cancer	6.02e-06	9.3e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—skin cancer	6.01e-06	9.3e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—skin cancer	5.98e-06	9.25e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—skin cancer	5.9e-06	9.13e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—skin cancer	5.87e-06	9.07e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—skin cancer	5.82e-06	8.99e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—skin cancer	5.81e-06	8.98e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NRAS—skin cancer	5.76e-06	8.9e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—skin cancer	5.76e-06	8.9e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—skin cancer	5.75e-06	8.89e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—skin cancer	5.69e-06	8.81e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.69e-06	8.79e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—skin cancer	5.64e-06	8.72e-05	CbGpPWpGaD
Imatinib—LCK—Disease—NRAS—skin cancer	5.63e-06	8.7e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO2—skin cancer	5.61e-06	8.68e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—skin cancer	5.56e-06	8.59e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—skin cancer	5.5e-06	8.51e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NRAS—skin cancer	5.45e-06	8.43e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—skin cancer	5.45e-06	8.43e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ERCC2—skin cancer	5.42e-06	8.38e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—skin cancer	5.41e-06	8.37e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—skin cancer	5.41e-06	8.37e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—skin cancer	5.32e-06	8.22e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—skin cancer	5.32e-06	8.22e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ERCC2—skin cancer	5.29e-06	8.18e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—skin cancer	5.25e-06	8.11e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—skin cancer	5.18e-06	8.01e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—skin cancer	5.13e-06	7.93e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—skin cancer	5.08e-06	7.86e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ERCC2—skin cancer	4.99e-06	7.71e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—skin cancer	4.96e-06	7.66e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ERCC2—skin cancer	4.94e-06	7.64e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NRAS—skin cancer	4.91e-06	7.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—skin cancer	4.91e-06	7.59e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—skin cancer	4.84e-06	7.49e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—skin cancer	4.69e-06	7.25e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—skin cancer	4.46e-06	6.9e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—skin cancer	4.4e-06	6.81e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—skin cancer	4.27e-06	6.6e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—skin cancer	4.23e-06	6.54e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ERCC2—skin cancer	4.22e-06	6.53e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—skin cancer	4.21e-06	6.51e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—skin cancer	4.2e-06	6.5e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—skin cancer	4.17e-06	6.45e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—skin cancer	4.12e-06	6.37e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—skin cancer	4.03e-06	6.23e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—skin cancer	3.99e-06	6.17e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NRAS—skin cancer	3.94e-06	6.09e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—skin cancer	3.94e-06	6.09e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—skin cancer	3.82e-06	5.9e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—skin cancer	3.76e-06	5.81e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—skin cancer	3.62e-06	5.6e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—skin cancer	3.59e-06	5.56e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—skin cancer	3.44e-06	5.32e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—skin cancer	3.39e-06	5.25e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ERCC2—skin cancer	3.26e-06	5.04e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—skin cancer	3.25e-06	5.03e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—skin cancer	3.17e-06	4.91e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—skin cancer	3.01e-06	4.66e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—skin cancer	2.99e-06	4.62e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—skin cancer	2.96e-06	4.58e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—skin cancer	2.88e-06	4.46e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—skin cancer	2.76e-06	4.27e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—skin cancer	2.53e-06	3.92e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—skin cancer	1.95e-06	3.02e-05	CbGpPWpGaD
